On the other hand, tirzepatide, while still dominating the market with 64% of total GLP-1 sales, saw monthly sales decline 15 per cent to 114 crore in March 2026, from 135 crore in February
Treatment is individualized
Change from Baseline (%) in Body Weight (Study 4 on Left and Study 5a on Right) with WEGOVY Injection Observed values for patients completing each scheduled visit, and estimates with multiple imputations from retrieved dropouts (RD-MI)
But the biological plausibility is sound, and some clinicians are incorporating this strategy into their long-term GLP-1 treatment plans
Presented for research literature review only Kemper RA et al
For example, Hashimoto's affects the thyroid, celiac disease involves the small intestine, and rheumatoid arthritis impacts the joints